Patent details

LUC00109 Product Name: Cimzia - certolizumab

Basic Information

Publication number:
LUC00109
Type:
SPC
SPC Type:
Medical
Basic Patent Number:
EP161549167
Legal Status:
Withdrawn
Application number:
LUC00109
First applicant's nationality:
Procedural language:
French

Marketing Authorization

Marketing Authorization Number:
EU/1/09/544/001; EU/1/09/544/002
Marketing Authorization Type:
Marketing Authorization Date:
06/10/2009
Marketing Authorization Status:
Claimed
Marketing Authorization Country:
Luxembourg (LU)

Dates

Filing date:
14/03/2019
First Marketing Authorization date:
06/10/2009
Grant date:
Activation date:
Publication date:
22/03/2019
Lapsed date:
Expiration date:
Renunciation date:
Revocation date:
Annulment date:
Basic SPC Expiration:
06/10/2024
SPC Extension Expiration:
06/10/2024
Rejection date:
Withdrawal date:
31/10/2019

Owner

From:
14/03/2019
 
 

Name:
UCB Pharma, S.A.
Address:
Allée de la Recherche 60, 1070 Bruxelles, Belgium (BE)

Agent

Name:
ARONOVA S.A.
From:
14/03/2019
Address:
PO Box 327, L-4004, ESCH-SUR-ALZETTE, Luxembourg (LU)
To:

Publication

Bulletin

1

Bulletin Heading:
SPC1
Bulletin edition number:
2019/05
Publication date:
11/04/2019
Description:
Section C : Published requests for Supplementary Protection Certificates – I1 publication

2

Bulletin Heading:
VRV
Bulletin edition number:
2019/12
Publication date:
07/11/2019
Description:
Section L: Applications for patents or supplementary protection certificates which have been withdrawn or are deemed to have been withdrawn (art. 32, 35.1, 39.5 of the law) Renunciation to a patent or supplementary protection certificate (Art. 72 of the law) Rejected applications for extensions for pediatric use of supplementary protections certificates